US Patent 9040050 Combination treatment of CD38-expressing tumors
Patent 9040050 was granted and assigned to Genmab A/S on May, 2015 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 9040050 Combination treatment of CD38-expressing tumors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
